Family Study of Affective and Anxiety Spectrum Disorders
Launched by NATIONAL INSTITUTE OF MENTAL HEALTH (NIMH) · Oct 30, 2003
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking into how mood disorders like depression and anxiety, as well as migraines, affect families. The goal is to understand how these conditions are passed down through generations and to identify risk factors that can lead to physical and mental health issues. By studying family members of all ages, including children aged 8 to 17, researchers hope to find ways to prevent and treat these problems.
To participate, individuals should be able to understand the interview questions and be willing to involve at least two family members. Participants will spend about 3 to 4 hours answering questions about their health, relationships, and how they cope with stress. The study team may visit homes or conduct interviews over the phone. This research will not only help identify patterns of mood disorders across different ages but also invite families to take part in future studies that track these issues over time.
Gender
ALL
Eligibility criteria
- • Since this study is based on systematic recruitment from the local community and other non-clinical settings such as screening protocols from volunteers, there are no specific diagnostic inclusion and exclusion criteria. However, the study targets individuals with mood spectrum conditions and migraine. Criteria for the specific subgroups of mood and anxiety disorders are presented in Table 1. Individuals who do not meet criteria are classified as controls.
- INCLUSION CRITERIA:
- • 1. the ability to comprehend the interview, and
- • 2. probands must agree to contact at least two relatives (contacting relatives is not required in cases where the participant is enrolled in just the mobile technologies assessments (EMA and Actigraphy).
- EXCLUSION CRITERIA:
- • The only exclusion criteria include impaired ability to comprehend the interview or inability to read.
- SPECIFIC INCLUSION AND EXCLUSION CRITERIA BY PROBAND GROUP:
- GENERAL INCLUSION CRITERIA:
- • The only inclusion criteria for the study are that the person be English-speaking and ability to read and comprehend the interview.
- BIPOLAR I INCLUSION CRITERIA:
- • Lifetime history of DSM-IV Bipolar I or Manic Episode
- BIPOLAR II INCLUSION CRITERIA:
- • Lifetime history of DSM-IV Bipolar II with duration of hypomania reduced to 2 or more days (according to RDC)
- MAJOR DEPRESSION INCLUSION CRITERIA:
- • Lifetime history of at least 2 episodes of DSM-IV Major Depression
- PANIC/GAD INCLUSION CRITERIA:
- • Lifetime history of DSM-IV diagnosis for Panic Disorder or GAD
- PHOBIAS INCLUSION CRITERIA:
- • Lifetime history of DSM-IV diagnosis for social anxiety disorder, agoraphobia, or specific phobias (greater than or equal to 3)
- MIGRAINE INCLUSION CRITERIA:
- • Lifetime history of IHS migraine with or without Aura
- GENERAL EXCLUSION CRITERIA:
- • The only exclusion criteria include impaired ability to comprehend the interview or inability to read.
About National Institute Of Mental Health (Nimh)
The National Institute of Mental Health (NIMH) is a leading federal agency dedicated to advancing the understanding and treatment of mental health disorders through innovative research and clinical trials. As part of the National Institutes of Health (NIH), NIMH focuses on a broad spectrum of mental health issues, including mood disorders, anxiety disorders, schizophrenia, and developmental disorders. By fostering collaboration among researchers, clinicians, and the community, NIMH aims to translate scientific discoveries into effective interventions and improve mental health outcomes for individuals across the lifespan. Through its commitment to rigorous research methodologies and ethical standards, NIMH plays a pivotal role in shaping the future of mental health care and policy.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bethesda, Maryland, United States
Bethesda, Maryland, United States
Patients applied
JR
KH
KS
Trial Officials
Kathleen R Merikangas, Ph.D.
Principal Investigator
National Institute of Mental Health (NIMH)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials